BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The following table identifies and provides the material terms of the Rule 10b5-1 trading arrangements (as such term is defined in Item 408 of Regulation S-K) adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended December 31, 2024.
| Name and Position | Plan Adoption / Termination | Plan Adoption / Termination Date | Expiration Date | Number of Shares Purchased (Sold) / Terminated under Plan |
|---|---|---|---|---|
| Sarah Aebersold, Chief Human Resources Officer | Adoption | December 11, 2024 | December 17, 2025 | (7,324) |
| Amy DuRoss, Lead Director | Adoption | December 13, 2024 | September 12, 2025 | (5,632) |
| Joydeep Goswami, Director | Adoption | December 13, 2024 | December 13, 2025 | (9,000) |
Non-Rule 10b5-1 Trading Arrangements
During the quarter ended December 31, 2024, none of our officers or directors adopted orterminated any non-Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.